Osiris Therapeutics to Present at 10th Annual JMP Securities Research Conference
COLUMBIA, Md.--(BUSINESS WIRE)--
Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company
focused on developing and marketing products to treat medical conditions
in the inflammatory, autoimmune, cardiovascular orthopedic and wound
care areas, announced today that C. Randal Mills, Ph.D., President and
Chief Executive Officer, is scheduled to present at the 10th
Annual JMP Securities Research Conference on Tuesday, May 10, 2011 at
12:00 p.m. PT.
A live audio webcast of the presentation may be accessed through the
Investors page of the Company's website at www.Osiris.com.
An audio replay of the webcast will be available for two weeks following
the conference.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is the leading stem cell company focused on
developing products to treat serious medical conditions in the
inflammatory, autoimmune, orthopedic, wound care and cardiovascular
areas. The company's pipeline of internally developed biologic drug
candidates under evaluation includes Prochymal for inflammatory,
autoimmune and cardiovascular indications, as well as Chondrogen for
arthritis in the knee. Osiris is a fully integrated company, with
capabilities in research, development, manufacturing and distribution of
stem cell products. Osiris has developed an extensive intellectual
property portfolio to protect the company's technology, including 47
U.S. and over 300 foreign patents.
Osiris and Genzyme formed a strategic alliance for the development and
commercialization of Prochymal and Chondrogen. Under the terms of the
agreement, Osiris retains commercialization rights to Prochymal and
Chondrogen in the United States and Canada. Genzyme holds these rights
in all other countries except Japan, where JCR Pharmaceuticals holds
rights to Prochymal for the treatment of patients with hematological
malignancies.
Osiris and Prochymal are registered trademarks of Osiris Therapeutics,
Inc. More information can be found on the company's website, www.Osiris.com.
(OSIR-G)
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements include statements about our expectations, beliefs, plans,
objectives, intentions, assumptions and other statements that are not
historical facts. Words or phrases such as "anticipate," "believe,"
"continue," "ongoing," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project" or similar words or phrases, or the
negatives of those words or phrases, may identify forward-looking
statements, but the absence of these words does not necessarily mean
that a statement is not forward-looking. Examples of forward-looking
statements include, but are not limited to, statements regarding the
following: our product development efforts; our clinical trials and
anticipated regulatory requirements and the ability to successfully
navigate these requirements; the success of our product candidates in
development; status of the regulatory process for our biologic drug
candidates; implementation of our corporate strategy; our financial
performance; our product research and development activities and
projected expenditures, including our anticipated timeline and clinical
strategy for Prochymal, Chondrogen and our other MSC and biologic drug
candidates; our cash needs; patents and proprietary rights; the safety
and ability of our potential products to treat disease and the results
of our scientific research; our plans for sales and marketing; our plans
regarding our facilities; types of regulatory frameworks we expect will
be applicable to our potential products; and results of our scientific
research. Forward-looking statements are subject to known and unknown
risks and uncertainties and are based on potentially inaccurate
assumptions that could cause actual results to differ materially from
those expected or implied by the forward-looking statements. Risks and
uncertainties related to our Collaboration Agreement with Genzyme for
the development and commercialization of Prochymal and Chondrogen
include, among others: typical business transactional risks; risks
related to product development and clinical trial design, performance
and completion; uncertainty of the success of Prochymal and Chondrogen
in clinical trials and their ability to treat disease; Genzyme's early
termination and opt-out rights; the ability of Osiris and Genzyme to
successfully navigate regulatory requirements and to manufacture and
commercialize products; and the uncertainty as to our ability to
successfully perform under the collaborative arrangement and earn
milestone and royalty payments thereunder. Our actual results could
differ materially from those anticipated in forward-looking statements
for many reasons, including the factors described in the section
entitled "Risk Factors" in our Annual Report on Form 10-K and other
Periodic Reports filed on Form 10-Q, with the United States Securities
and Exchange Commission. Accordingly, you should not unduly rely on
these forward-looking statements. We undertake no obligation to publicly
revise any forward-looking statement to reflect circumstances or events
after the date of this press release or to reflect the occurrence of
unanticipated events.
Osiris Therapeutics, Inc.
Erica Elchin, 443-545-1834
OsirisPR@Osiris.com
Source: Osiris Therapeutics, Inc.
News Provided by Acquire Media
Print page |
E-mail page
| 
Download PDF
|
Add to briefcase